Literature DB >> 7504935

A new type of G-->A hypermutation affecting human immunodeficiency virus.

J E Fitzgibbon1, S Mazar, D T Dubin.   

Abstract

A form of G-->A hypermutation preferentially affecting GA dinucleotides of genomic RNA has been found to occur in retroviral systems ("type 1"). In a detailed longitudinal study of an AIDS patient we have observed a new type of G-->A hypermutation, which preferentially affects one or more 5' G residues in runs of G's. HIV-1 proviral DNA samples obtained at widely separate times during this patient's course contained representatives of this type of G-->A hypermutation, designated "type 2." We propose that G-->A hypermutation is caused by a mutated form of the HIV-1 reverse transcriptase; and that hypermutated DNA may persist for long periods in infected patients, perhaps as proviral DNA in long-lived cell lineages. Like type 1 G-->A hypermutation, type 2 G-->A hypermutation may contribute to the heterogeneity of replicating pools of HIV by recombination.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504935     DOI: 10.1089/aid.1993.9.833

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

2.  G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.

Authors:  Tara L Kieffer; Patty Kwon; Richard E Nettles; Yefei Han; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs.

Authors:  Dan Turner; Bluma Brenner; Daniela Mosis; Chen Liang; Mark A Wainberg
Journal:  MedGenMed       Date:  2005-03-24

4.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 5.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

Review 7.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

Review 8.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

9.  Lethal mutagenesis of HIV with mutagenic nucleoside analogs.

Authors:  L A Loeb; J M Essigmann; F Kazazi; J Zhang; K D Rose; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.